RESUMO
INTRODUCTION: Treatments for hidradenitis suppurativa (HS) have changed in the last decade. In this context, we studied how management practices have shifted. METHODS: We analyzed the National Ambulatory Medical Care Survey (NAMCS) from 2010 to 2016 to assess current treatment practices for HS. RESULTS: There were 1.78 (95% confidence interval 1.35, 2.22) million visits. Antibiotics were observed at 55.7% of visits and observations remained stable over time (p = .9, odds ratio 0.99 [0.73, 1.3]). Pain medications were observed at 15.5% of visits and observations remained stable over time (p = .4, odds ratio [0.87 [0.61, 1.2]). Biologic agents were observed at 0.9% of visits and observations remained stable over time (p = .4, odds ratio 0.61 [0.21, 1.7]). Systemic immunomodulators were observed at 2.6% of visits and observations remained stable over time (p = .08, odds ratio 0.42 [0.12, 1.1]). 100% of biologic agents and 88% of systemic immunomodulators were prescribed by dermatologists. DISCUSSION: The use of biologic agents did not increase in this interval, but it is higher than in an earlier assessment of the NAMCS. Nearly all systemic immunomodulators are prescribed by dermatologists. The ambulatory uptake of these agents did not alter the use of other treatment modalities within this timeframe.
Assuntos
Hidradenite Supurativa , Assistência Ambulatorial , Fatores Biológicos/uso terapêutico , Terapia Biológica , Pesquisas sobre Atenção à Saúde , Hidradenite Supurativa/tratamento farmacológico , HumanosRESUMO
BACKGROUND: Until recently, treatment of atopic dermatitis has been limited to topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic immunomodulatory agents. With improved understanding of the pathogenesis underlying atopic dermatitis, targeted oral small molecules and topical agents are being developed. OBJECTIVE: Discuss efficacy and safety profiles of emerging oral small molecules and targeted topical agents in phase 2 and 3 clinical trials. METHODS: A systemic literature review was conducted to identify results of randomized, placebo-controlled trials of oral small molecules and topical Janus kinase inhibitors up to March 1 2020 for the treatment of atopic dermatitis. RESULTS: Three novel oral small molecules, abrocitinib, upadacitinib, and baricitinib, demonstrated improvement of clinical severity, pruritus, and quality of life with acceptable safety profiles. Apremilast, a phosphodiesterase inhibitor, was less efficacious with use limited by adverse effects. Two novel topical agents, ruxolitinib and delgocitinib, were effective and well-tolerated. CONCLUSIONS: Targeted therapeutics including oral small molecules and topical agents show promise for the treatment of atopic dermatitis. The use of validated core measures is necessary for future trials in order to adequately compare agents and progress evidence-based medicine.
Assuntos
Dermatite Atópica , Fármacos Dermatológicos , Inibidores de Janus Quinases , Inibidores de Calcineurina/efeitos adversos , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/patologia , Fármacos Dermatológicos/uso terapêutico , Humanos , Inibidores de Janus Quinases/uso terapêutico , Qualidade de Vida , Resultado do TratamentoRESUMO
BACKGROUND: The mainstay of atopic dermatitis treatment has been largely unchanged over the last few decades. With improved understanding of the immunologic pathways underlying atopic dermatitis in recent years, targeted biologic therapies are being developed. OBJECTIVE: Discuss efficacy and safety profiles of emerging biologics in phase 2 and 3 clinical trials. METHODS: A systemic literature review was conducted to identify results of randomized, placebo-controlled trials of monoclonal antibodies up to March 1, 2020 for the treatment of atopic dermatitis. RESULTS: Targeted biologics appear to have acceptable safety profiles. Dupilumab, lebrikizumab, and nemolizumab demonstrate efficacy as agents producing improvement in clinical severity and pruritus. CONCLUSIONS: The growing class of biologics shows promise in meeting the needs of treatment-resistant atopic dermatitis. The use of validated core measurements is necessary for future trials in order to adequately compare agents and progress evidence-based medicine.
Assuntos
Produtos Biológicos , Dermatite Atópica , Produtos Biológicos/uso terapêutico , Terapia Biológica , Dermatite Atópica/tratamento farmacológico , Humanos , Imunoterapia , Prurido/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Índice de Gravidade de Doença , Resultado do TratamentoAssuntos
Assistência Ambulatorial/tendências , Fármacos Dermatológicos/administração & dosagem , Dermatologia/tendências , Fototerapia/tendências , Padrões de Prática Médica/tendências , Administração Oral , Administração Tópica , Assistência Ambulatorial/métodos , Assistência Ambulatorial/estatística & dados numéricos , Produtos Biológicos/administração & dosagem , Inibidores de Calcineurina/administração & dosagem , Estudos Transversais , Dermatologia/métodos , Dermatologia/estatística & dados numéricos , Prescrições de Medicamentos/estatística & dados numéricos , Feminino , Glucocorticoides/administração & dosagem , Humanos , Masculino , Visita a Consultório Médico/estatística & dados numéricos , Visita a Consultório Médico/tendências , Fototerapia/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Psoríase , Vitamina D/administração & dosagem , Vitamina D/análogos & derivadosRESUMO
BACKGROUND: Moderate-to-severe psoriasis generally requires systemic therapy, and is often undertreated. OBJECTIVE: To determine and analyze what courses of treatment and in what frequency are being utilized to combat psoriasis in the United States. METHODS: Analysis of data from the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) of the National Center for Health Statistics. Data were analyzed to examine the prevalence of different therapy techniques to combat psoriasis from 1993 through 2010. The trends for phototherapy, methotrexate (MTX), retinoids, cyclosporine A (CSA), systemic steroids, and biologics were all analyzed over the entire 18-year period and independently before and after the introduction of biologics in 2002. RESULTS: From 1993 to 2010, the trend for total systemic treatments has not significantly increased (P=0.5). Frequency of phototherapy treatments significantly decreased from 1993 to 2010 (P<0.001). Since the introduction of biologics in 2002, their frequency has significantly increased, becoming the most frequently used treatment from 2008-2010 (P<0.0001). LIMITATIONS: Severity of psoriasis was not recorded in the NAMCS and NHAMCS. CONCLUSIONS: The frequency of systemic treatments to treat psoriasis has not significantly increased from 1993 to 2010. Despite the introduction of biologics, it appears that little progress has been made in reducing under-treatment of moderate-to-severe psoriasis.
Assuntos
Fármacos Dermatológicos/administração & dosagem , Dermatologia/tendências , Psoríase/tratamento farmacológico , Anti-Inflamatórios/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Ciclosporina/administração & dosagem , Humanos , Metotrexato/administração & dosagem , Fototerapia/estatística & dados numéricos , Psoríase/patologia , Retinoides/administração & dosagem , Índice de Gravidade de Doença , Inquéritos e Questionários , Estados UnidosRESUMO
BACKGROUND: Atopic dermatitis (AD) is a prevalent skin disorder with significant cost of treatment. Several prescription device moisturizers have been approved by the FDA to treat AD but are significantly more expensive than well-crafted over-the-counter (OTC) moisturizers. No studies have been performed to compare both the clinical efficacy and cost-efficacy of these prescription devices to OTC moisturizers. PURPOSE: The purpose of this study is to compare the clinical efficacy and cost-efficacy of a glycyrrhetinic acid-containing barrier repair cream (BRC-Gly, Atopiclair®), a ceramide-dominant barrier repair cream (BRC-Cer, EpiCeram®) and an OTC petroleum-based skin protectant moisturizer (OTC-Pet, Aquaphor Healing Ointment®) as monotherapy for mild-to-moderate AD in children. METHODS: Thirty-nine patients, age 2-17 years, with mild-to-moderate AD were randomized 1:1:1 to receive one of three treatments-BRC-Gly, BRC-Cer or OTC-Pet-with instructions to apply the treatment three times daily for three weeks. Disease severity and improvement was assessed at baseline and on days 7 and 21. RESULTS: No statistically significant difference for any efficacy assessment was found between the three groups at each time point. The OTC-Pet was found to be at least 47 times more cost-effective than BRC-Gly or BRC-Cer. LIMITATIONS: The relatively small sample size of 39 subjects was not sufficient to establish OTC-Pet as superior treatment in AD. CONCLUSIONS: OTC-Pet is as effective in treating mild-to-moderate AD as both BRC-Gly and BRC-Cer and is at least 47 times more cost-effective. NAME OF REGISTRY: II-AF-ATD-Aquaphor, Comparing the Efficacy and Cost-Effectiveness of Aquaphor to Atopiclair and EpiCeram in Children with Mild to Moderate Atopic Dermatitis. REGISTRATION IDENTIFIER: NCT01093469.
Assuntos
Dermatite Atópica/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Emolientes/uso terapêutico , Administração Cutânea , Adolescente , Ceramidas/administração & dosagem , Ceramidas/economia , Ceramidas/uso terapêutico , Criança , Pré-Escolar , Colesterol/administração & dosagem , Colesterol/economia , Colesterol/uso terapêutico , Análise Custo-Benefício , Dermatite Atópica/patologia , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/economia , Gorduras na Dieta/administração & dosagem , Gorduras na Dieta/economia , Gorduras na Dieta/uso terapêutico , Método Duplo-Cego , Combinação de Medicamentos , Emolientes/administração & dosagem , Emolientes/economia , Ácidos Graxos/administração & dosagem , Ácidos Graxos/economia , Ácidos Graxos/uso terapêutico , Feminino , Ácido Glicirretínico/administração & dosagem , Ácido Glicirretínico/economia , Ácido Glicirretínico/uso terapêutico , Humanos , Masculino , Medicamentos sem Prescrição/administração & dosagem , Medicamentos sem Prescrição/economia , Medicamentos sem Prescrição/uso terapêutico , Vaselina/administração & dosagem , Vaselina/economia , Vaselina/uso terapêutico , Extratos Vegetais/administração & dosagem , Extratos Vegetais/economia , Extratos Vegetais/uso terapêutico , Medicamentos sob Prescrição/administração & dosagem , Medicamentos sob Prescrição/economia , Medicamentos sob Prescrição/uso terapêutico , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
CONTEXT: Skin diseases are common occupational illnesses for migrant farmworkers. Farmworkers face many barriers in accessing health care resources. PURPOSE: Framed by the Health Behavior Model, the purpose of this study was to assess health care utilization for skin disease by migrant Latino farmworkers. METHODS: Three hundred and four migrant and seasonal Latino farmworkers in North Carolina were enrolled in a longitudinal study of skin disease and health care utilization over a single agricultural season. Self-reported and dermatologist-diagnosed skin condition data were collected at baseline and at up to 4 follow-up assessments. Medical visit rates were compared to national norms. FINDINGS: Self-reported skin problems and diagnosed skin disease were common among farmworkers. However, only 34 health care visits were reported across the entire agricultural season, and none of the visits were for skin diseases. Nevertheless, self-treatment for skin conditions was common, including use of non-prescription preparations (63%), prescription products (9%), and home remedies (6%). General medical office visits were reported in 3.2% of the assessments, corresponding to 1.6 office visits per person year. CONCLUSIONS: The migrant farmworker population consists largely of young men who make little use of clinic services. Skin conditions are very common among these workers, but use of medical services for these conditions is not common. Instead, farmworkers rely primarily on self-treatment. Clinic-based studies of farmworker skin conditions will not account for most injury or disease in this population and have the potential for biased estimates.
Assuntos
Doenças dos Trabalhadores Agrícolas/etnologia , Hispânico ou Latino/estatística & dados numéricos , Visita a Consultório Médico/estatística & dados numéricos , Aceitação pelo Paciente de Cuidados de Saúde/etnologia , Serviços de Saúde Rural/estatística & dados numéricos , Dermatopatias/etnologia , Migrantes/estatística & dados numéricos , Adolescente , Adulto , Doenças dos Trabalhadores Agrícolas/diagnóstico , Doenças dos Trabalhadores Agrícolas/tratamento farmacológico , Dermatologia/estatística & dados numéricos , Escolaridade , Humanos , Masculino , Medicina Tradicional , Pessoa de Meia-Idade , Medicamentos sem Prescrição/uso terapêutico , North Carolina/epidemiologia , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Medicamentos sob Prescrição/uso terapêutico , Prevalência , Dermatopatias/diagnóstico , Dermatopatias/tratamento farmacológico , Migrantes/classificação , Adulto JovemAssuntos
Acitretina/administração & dosagem , Serviços de Assistência Domiciliar , Ceratolíticos/administração & dosagem , Psoríase/tratamento farmacológico , Psoríase/radioterapia , Terapia Ultravioleta , Acitretina/uso terapêutico , Relação Dose-Resposta a Droga , Humanos , Ceratolíticos/uso terapêutico , Satisfação do Paciente , Psoríase/fisiopatologia , Qualidade de Vida , Índice de Gravidade de DoençaRESUMO
BACKGROUND: In the treatment of psoriasis, patient adherence to oral medications is poor and even worse for topical therapy. However, few data exist about adherence rates to home phototherapy, adding to concerns about the appropriateness of home phototherapy as a psoriasis treatment option. OBJECTIVE: We sought to assess adherence to both oral acitretin and home ultraviolet B phototherapy for the treatment of psoriasis. METHODS: In all, 27 patients with moderate to severe psoriasis were treated with 10 to 25 mg of acitretin daily, combined with narrowband ultraviolet B, 3 times weekly at home, for 12 weeks. Adherence to acitretin was monitored by an electronic monitoring medication bottle cap, and to phototherapy by a light-sensing data logger. RESULTS: Adherence data were collected on 22 patients for acitretin and 16 patients for adherence to ultraviolet B. Mean adherence to acitretin decreased steadily during the 12-week trial (slope -0.24), whereas mean adherence to home phototherapy remained steady at 2 to 3 d/wk. Adherence was similar between patients who reported side effects and those who did not. LIMITATIONS: Small sample size and lack of follow-up on some patients were limitations of this study. CONCLUSIONS: Adherence rates to home phototherapy were very good and higher than adherence rates for the oral medication. Side effects of treatment were well tolerated in this small group and did not affect use of the treatment. Home phototherapy with acitretin may be an appropriate option for some patients with extensive psoriasis.
Assuntos
Acitretina/uso terapêutico , Cooperação do Paciente/estatística & dados numéricos , Psoríase/tratamento farmacológico , Psoríase/radioterapia , Terapia Ultravioleta , Administração Oral , Adulto , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Skin disease is common among migrant Latino farmworkers. These workers rarely use formal health care services but commonly engage in self-treatment of their skin disease. We present a patient with dermatitis who self-treated with bleach. This patient illustrates a common practice that exacerbates skin disease and sheds light on social and cultural factors of which health care providers serving this community should be aware.
Assuntos
Doenças dos Trabalhadores Agrícolas/terapia , Dermatite Irritante/etiologia , Detergentes/efeitos adversos , Automedicação/efeitos adversos , Hipoclorito de Sódio/efeitos adversos , Doenças dos Trabalhadores Agrícolas/patologia , Atitude Frente a Saúde/etnologia , Dermatite de Contato/patologia , Dermatite de Contato/terapia , Dermatite Irritante/etnologia , Dermatite Irritante/patologia , Detergentes/administração & dosagem , Hispânico ou Latino , Humanos , Masculino , Medicina Tradicional , Pessoa de Meia-Idade , Automedicação/métodos , Hipoclorito de Sódio/administração & dosagem , Migrantes , Estados UnidosAssuntos
Antifúngicos/uso terapêutico , Betametasona/uso terapêutico , Clotrimazol/uso terapêutico , Prescrições de Medicamentos/estatística & dados numéricos , Assistentes Médicos/estatística & dados numéricos , Dermatopatias/tratamento farmacológico , Dermatite/tratamento farmacológico , Dermatologia , Dermatomicoses/tratamento farmacológico , Combinação de Medicamentos , Humanos , Atenção Primária à Saúde , Qualidade da Assistência à SaúdeRESUMO
BACKGROUND: Patients with moderate-to-severe psoriasis frequently require systemic treatment and these medications may be associated with adverse effects. Little is known about the frequency of these events when systemic agents are used in true clinical practice. OBJECTIVE: To determine the frequency of adverse events associated with various systemic psoriasis therapies. METHODS: A retrospective chart review of 753 patients treated in an academic dermatology practice was performed to identify the frequency of adverse events. Poisson regression was used to estimate the odds of significant events for each systemic therapy; UVB-treated patients served as a control population. RESULTS: Methotrexate seemed to be the most prescribed medication. Adverse events were noted with all forms of systemic psoriasis therapy. The highest event rate was seen with oral retinoids, though most of these were considered minor (64%). Cyclosporine had the highest significant adverse event rate (0.9 events/patient). For 'significant' adverse events, oral agents had an adjusted odds ratio>6 compared to standard UVB therapy. The highest risk was for cyclosporine (OR = 20.3); however, the estimate was imprecise (95% confidence interval [4.3, 96.6]). CONCLUSIONS: Traditional psoriasis therapies are associated with significant adverse events in some patients despite toxicity-sparing approaches such as combination therapy. Clinicians need to be aware of screening for adverse events in order to best ensure the safety of their patients and to maximize the efficacy of a given agent. There is still a need for the development of safe and effective treatments for patients with moderate-to-severe psoriasis.
Assuntos
Fármacos Dermatológicos/efeitos adversos , Psoríase/terapia , Adulto , Idoso , Produtos Biológicos/efeitos adversos , Ciclosporina/efeitos adversos , Feminino , Humanos , Hidroxiureia/efeitos adversos , Masculino , Metotrexato/efeitos adversos , Pessoa de Meia-Idade , Terapia PUVA/efeitos adversos , Retinoides/efeitos adversos , Estudos RetrospectivosRESUMO
Because the number of dermatologists remains stable, patients with medical dermatologic conditions such as psoriasis may find it increasingly difficult to access dermatological treatment. Measuring the competition in the marketing of dermatologic care may provide insight into the availability of dermatology services. The purpose of this study was to determine to what extent dermatologists are using the Yellow Pages to advertise to patients with psoriasis. We performed a quantitative and qualitative assessment of dermatologists' Yellow Pages advertisements in small cities and the ten largest metropolitan regions in the country. Per capita, more advertisements were found in smaller markets than larger markets and a higher percentage was descriptive rather than just a name, address and phone number. Cosmetic and surgical advertisements were more common than psoriasis ads in both markets. Cosmetic ads were more prevalent in larger markets. In all regions, psoriasis and psoriasis treatment ads were least common. These findings raise the concern that incentive structures in the United States healthcare system do not adequately support delivery of dermatologic care for psoriasis. Efforts to promote psoriasis care should be encouraged.
Assuntos
Publicidade/estatística & dados numéricos , Dermatologia , Fototerapia/estatística & dados numéricos , Psoríase/terapia , Humanos , Internet , Estados Unidos , Recursos HumanosRESUMO
Historically, severe psoriasis frequently required inpatient hospitalization for several weeks to reduce symptoms and prevent morbidity and mortality, Despite declining hospitalization rates there remain patients who undergo severe, acute psoriasis exacerbations requiring inpatient care. The majority of the literature describes the treatment of psoriasis in the outpatient setting. We review the inherent differences between the inpatient and outpatient management of psoriasis along several dimensions and discuss an approach to the inpatient treatment of severe psoriasis based upon therapeutic rate of onset, efficacy, and safety. The inpatient setting benefits from and lends itself to use of rapid acting, highly effective agents. Given the acute nature of psoriasis inpatient episodes, the risks associated with long-term use of a treatment are far less important in inpatient setting treatment planning than they are in the outpatient setting.
Assuntos
Psoríase/terapia , Terapia Biológica , Hospitalização/economia , Humanos , Imunossupressores/uso terapêutico , Pacientes Internados , Fototerapia , Pleistophora , Psoríase/tratamento farmacológico , Psoríase/economiaRESUMO
PURPOSE: The purpose of this article is to provide a review of the cost of psoriasis therapies from two sources as well as compare the average wholesale price (AWP), as listed in the 2003 Drug Topics Red Book to that of a popular Internet pharmacy. METHODS: Prices of therapies were obtained two ways: the AWP was recorded from the 2003 Drug Topics Red Book. A range and average price per gram (or mL) were calculated based on the smallest size or quantity available. In addition, a price comparison was made to values as they were reported online at drugstore.com. Monthly cost estimates were based on average systemic dosing and for topicals, 18 g/month (for 1% body surface area [BSA] involvement). RESULTS: The prices of psoriatic treatment medications vary considerably--from the relatively inexpensive topical corticosteroids to the more costly biologic therapies. In the category of corticosteroids, a trend was evident between the overall price per gram of each class and the potency of each class. Class I and VI corticosteroids had an average price per gram (or mL) of dollars 2.08 (dollars 37/month/1% BSA) and dollars 0.86 (dollars 15/month/1% BSA), respectively. Nonsteroidal topical treatments had an average price per gram (or mL) dollars 2.18 (dollars 39/month/1% BSA). Systemic therapies have a wide range of costs. The total monthly expense, based on estimated average dosing, was calculated for methotrexate, acitretin, and cyclosporine and were dollars 78.60, dollars 400.50, and dollars 735.00, respectively. Biologic therapies designed for continuous use cost roughly dollars 1,300/month. DISCUSSION: There are numerous treatment options for psoriasis with a wide range of costs. In addition to significant challenges from a scientific perspective, psoriasis treatment is further complicated by the cost of the numerous medications. Prices reported in the AWP were similar in many instances to those listed at an Internet pharmacy. Many considerations should go into therapy selection for psoriasis and a comprehensive approach that includes cost will likely provide the best patient care.
Assuntos
Custos de Medicamentos/estatística & dados numéricos , Custos de Cuidados de Saúde/estatística & dados numéricos , Seleção de Pacientes , Psoríase/terapia , Anti-Inflamatórios/classificação , Anti-Inflamatórios/economia , Controle de Custos , Análise Custo-Benefício , Fármacos Dermatológicos/classificação , Fármacos Dermatológicos/economia , Humanos , Imunossupressores/economia , Fototerapia/economia , Mecanismo de Reembolso/economia , Equivalência TerapêuticaRESUMO
BACKGROUND: Combination treatment in psoriasis may be common, logical, and appropriate, even if not well tested or well documented by clinical trials. While oral retinoids such as acitretin can be used as monotherapy, efficacy can be further augmented by combination use with other agents. Similarly, because of its safety profile, acitretin can be added in low doses to help patients who have not achieved adequate control with other psoriasis treatments. OBJECTIVE: The purpose of this study was to assess how oral retinoids are used in combination with other drugs to treat psoriasis. METHODS: We assessed the use of acitretin and other oral retinoids for the treatment of psoriasis using two sources of information: nationally representative survey data from the National Ambulatory Medical Care Survey (NAMCS) and local data obtained by chart review of 518 patients seen in a university dermatology clinic. RESULTS: In the NAMCS, oral retinoids were prescribed with other psoriasis medications at 71% of visits. In the chart review, combination use was even more frequent (96% of subjects were on combination treatment) and included combinations of acitretin with topicals, phototherapy, and other systemic treatments. Adverse events were reported in 53% of patients treated with acitretin, although none were severe. CONCLUSION: Use of acitretin in combination with many other psoriasis treatments is a common practice. Mucocutaneous side effects of oral retinoids are common but with appropriate dosing are generally mild.
Assuntos
Acitretina/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Psoríase/tratamento farmacológico , Retinoides/administração & dosagem , Administração Oral , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
Phototherapy is an established treatment modality for psoriasis. The use of phototherapy for psoriasis appears to be in decline in nonfederal and non-university-based settings. We used data from the National Ambulatory Medical Care Survey to estimate the number of visits for phototherapy and psoralen ultraviolet A-range (PUVA) light therapy from 1993 to 1998. There were 873,000 visits for UV light therapy in 1993-1994, 189,000 in 1995-1996, and 53,000 in 1997-1998 (P <.0001). There were 175,000 psoralen visits in 1993-1994, 61,000 in 1995-1996, and 25,000 in 1997-1998 (P =.0053). Similar decreases in phototherapy visits occurred in our university-based practice. The decline in phototherapy represents decreased utilization of a safe and effective treatment for psoriasis.
Assuntos
Terapia PUVA/estatística & dados numéricos , Fototerapia/estatística & dados numéricos , Psoríase/terapia , Pesquisas sobre Atenção à Saúde , Humanos , Estados UnidosRESUMO
Clotrimazole-betamethasone diproprionate (C-BMV) is a fluorinated, high potency topical steroid that has been formulated with clotrimazole in the brand-named product, Lotrisone. The product is frequently used inappropriately in intertriginous areas, particularly in children. The following evaluates the use of this combination based upon a survey of 106 US-based pediatricians with at least two years post-residency, who attended the 1999 American Academy of Pediatrics. Of pediatricians who prescribe C-BMV, 23% prescribe it for diaper dermatitis. 11% of C-BMV prescriptions exceed the recommended duration of therapy. Only 18% of prescribing pediatricians correctly identify "Lotrisone" as a high potency steroid. There is no significant association between knowledge of C-BMV potency and frequency of use (p>.1). These self-reported data confirm and complement the findings of previous studies that used representative national data to assess the use of C-BMV. Pediatricians continue to utilize C-BMV in inappropriate settings, such as diaper dermatitis, regardless of their knowledge of the agent's potency. Our advice is to refrain from using high-potency steroids, such as C-BMV, in pediatric cases as there are more appropriate, safer alternatives with many fewer side effects.